VERAXA Biotech AG (NASDAQ: VRXA) announced on July 20 that it has received Scientific Advice from Germany’s Paul-Ehrlich-Institute (PEI), providing regulatory feedback on the biological rationale and non-clinical development strategy for its lead BiTAC-TCE program. The PEI, Germany’s federal institute for vaccines and biomedicines, offered guidance that supports the company’s proposed development approach, including safety assessments and the overall plan to advance the novel therapeutic platform toward clinical studies.
This regulatory milestone is significant for VERAXA as it helps reduce development uncertainty by offering early clarity from regulators before the company initiates clinical trials. The company believes the advice aligns with its strategy to develop bispecific T-cell engagers, which are designed to harness the immune system to target cancer cells. The lead candidate previously generated encouraging preclinical data presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting, demonstrating the platform’s potential.
VERAXA continues to build a diversified oncology pipeline that includes bispecific T-cell engagers, antibody-drug conjugates (ADCs), and other engineered antibody formats. The positive regulatory feedback from the PEI (https://ibn.fm/zBiDU) marks progress in the company’s manufacturing and development efforts as it advances next-generation antibody therapeutics for cancer.
As VERAXA prepares its BiTAC-TCE candidate for clinical development, the Scientific Advice procedure provides a framework for regulatory expectations, potentially accelerating the path to first-in-human studies. The company’s focus on innovative antibody formats aims to address unmet needs in oncology, and this regulatory endorsement may enhance investor confidence in the platform.
For more information about VERAXA and its pipeline, visit the company’s newsroom at https://ibn.fm/VRXA.
